We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Advanced Melanoma

Journal Scan / Research · October 05, 2022

Patient-Reported Tolerability of Adjuvant Ipilimumab vs High-Dose Interferon for Resected High-Risk Stage III–IV Melanoma

Quality of Life Research: an international journal of quality of life aspects of treatment, care and rehabilitation

 

Additional Info

Disclosure statements are available on the authors' profiles:

Quality of Life Research: an international journal of quality of life aspects of treatment, care and rehabilitation
Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609
Qual Life Res 2022 Aug 27;[EPub Ahead of Print], LE McLouth, Y Zheng, S Smith, FS Hodi, UN Rao, GI Cohen, TT Amatruda, SR Dakhil, BD Curti, I Nakhoul, SR Chandana, CL Bane, DE Marinier, SJ Lee, VK Sondak, JM Kirkwood, AA Tarhini, LI Wagner

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading